JMP Securities Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $16.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective raised by equities researchers at JMP Securities from $15.00 to $16.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price target points to a potential upside of 107.52% from the stock’s previous close.

Several other research analysts have also commented on BCRX. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Trading Up 2.7 %

Shares of BCRX stock traded up $0.20 on Tuesday, reaching $7.71. The company’s stock had a trading volume of 1,480,826 shares, compared to its average volume of 3,395,075. The stock’s fifty day simple moving average is $6.69 and its 200-day simple moving average is $5.77. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $7.93. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -7.21 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to analysts’ expectations of $98.30 million. During the same period last year, the business posted ($0.24) earnings per share. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. Equities research analysts forecast that BioCryst Pharmaceuticals will post -0.65 earnings per share for the current year.

Insider Activity at BioCryst Pharmaceuticals

In other news, CFO Anthony Doyle acquired 36,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the completion of the acquisition, the chief financial officer now directly owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other BioCryst Pharmaceuticals news, Director Machelle Sanders sold 4,689 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the completion of the transaction, the director now directly owns 27,742 shares in the company, valued at $166,452. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Anthony Doyle purchased 36,300 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were acquired at an average price of $5.57 per share, for a total transaction of $202,191.00. Following the purchase, the chief financial officer now directly owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The disclosure for this purchase can be found here. Insiders bought 103,601 shares of company stock worth $596,338 over the last three months. 4.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Los Angeles Capital Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 8.9% during the second quarter. Los Angeles Capital Management LLC now owns 97,577 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 7,963 shares during the last quarter. TD Asset Management Inc purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $1,487,000. Rhumbline Advisers grew its stake in shares of BioCryst Pharmaceuticals by 6.3% during the second quarter. Rhumbline Advisers now owns 318,665 shares of the biotechnology company’s stock worth $1,969,000 after acquiring an additional 18,916 shares during the last quarter. nVerses Capital LLC purchased a new stake in BioCryst Pharmaceuticals in the second quarter valued at approximately $63,000. Finally, Signaturefd LLC increased its holdings in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,599 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.